Jesse Schulman

Cooley advised Morgan Stanley, Jefferies, Citigroup and Guggenheim Securities as the underwriters of Zenas BioPharma’s $225 million initial public offering.

Cooley advised Ionis Pharmaceuticals (Nasdaq: IONS), a biotechnology research company inventing medicines that bring better futures to people with serious diseases, on its $500.3 million underwritten public offering of common stock.

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Cooley advised the underwriters in Vistagen Therapeutics’ $100 million follow-on offering of common stock, pre-funded warrants, and two tranches of common stock warrants, with Jefferies, Stifel and William Blair acting as lead book-running managers. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders. Partners Denny Won, Charlie Kim and Courtney Tygesson led the Cooley team.

Cooley advised TPB Acquisition Corporation I, a special purpose acquisition company sponsored by The Production Board, in its business combination agreement that will result in Lavoro Limited, a leading agricultural inputs retailer in Latin America, becoming a US publicly listed company with an implied initial enterprise value of approximately $1.2 billion.